GrowBlox Sciences, Inc. (OTCQB: GBLX) saw its share volume soar on May 30th with 410,875 shares exchanging hands, 12 times higher than its three month daily average volume of 32,270.
This uptick in volume comes after GrowBlox Sciences, a biotechnology and research company, announced that The Company has relocated its corporate headquarters to Las Vegas, Nevada and has centralized its CFO and team in the heart of Clark County in anticipation of its Nevada project.
GrowBLOX Sciences CFO, Steven Weldon, has relocated from Orlando, Florida to Clark County in order to build upon the momentum of The Company's licensing applications, as it awaits final approval from the County Commission. GrowBLOX Sciences has applied for three licenses in Clark County, one license for cultivation and two licenses for dispensaries, utilizing their patent pending proprietary indoor growing technology. The Company is confident in its Nevada initiatives and has relocated its forces as a driving catalyst for their future operations.
"Relocating to Nevada has been an exciting endeavor for not only myself, but The Company as well. Nevada has been the preeminent force in licensing and regulatory commissions for sometime and has a proven record of success. Working with the local municipalities in Clark County is a driving force in moving this processes forward and we are thrilled to be a part of it and set the standard for innovation and cultivation," said CFO, Steven Weldon.
GBLX closed the day at $2.42, 40.7% higher than its previous close of $1.72.
PennyPickAlerts.com is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential, sign up here:
Cynapsus Therapeutics Grants Stock Options
Cynapsus Therapeutics Inc. (OTCQX: CYNAF) saw its share volume skyrocket on May 30th with 1,081,904 shares exchanging hands, five times higher than its three month daily average volume of 191,190 shares.
Cynapsus Therapeutics, a specialty pharmaceutical company, recently announced that the Corporation's Board of Directors granted stock options to acquire 2,256,000 common shares.
The stock options were granted to officers, directors, employees and a consultant of the Corporation at an exercise price equal to $0.65 per share, and expire 5 years from the date of grant. One third of the options granted will vest immediately, one-third will vest in 6 months and one-third will vest in 12 months. Of the total, 884,000 stock options were granted to Anthony Giovinazzo (President & CEO), 355,000 to Andrew Williams (COO/CFO), 350,000 to Albert Agro (CMO), 102,000 to Rochelle Stenzler (Director), 64,000 to Ronald Hosking (Director), 56,000 to Perry Molinoff (Director), 52,000 to Alan Ryley (Director), 42,000 to Tomer Gold (Director) and 25,000 to Nan Hutchinson (Director). The remaining 326,000 stock options were granted to employees and a consultant of the Corporation.
CYNAF closed the day at $.576, 21.14% higher than its previous close of $.4755.
Senesco Technologies Acquires Fabrus, Inc.
Senesco Technologies, Inc. (OTCQB: SNTI) saw its share volume soar on May 30th with 267,500 shares exchanging hands, 50 times higher than its three month daily average volume of 18,602 shares.
Senesco Technologies recently completed its acquisition of Fabrus, Inc. ("Fabrus"), an OPKO Health, Inc. portfolio company focused on expanding the clinical impact of antibodies by addressing drug targets resistant to traditional antibody discovery methods.
Fabrus has been successful in generating antibodies against difficult, therapeutically important cell surface receptors and ion channels resulting in an internal pipeline that includes next generation antibodies targeting cancer and inflammation. It also has collaborations in place with large pharma and biotech companies to discover antibodies to their targets. Dr. Vaughn V. Smider, founder of Fabrus and faculty member at The Scripps Research Institute in La Jolla, CA, will become acting CEO of Senesco.
Senesco Technologies is a clinical-stage biotech company specializing in cancer therapeutics. Its proprietary gene regulation technology has demonstrated the ability to kill cancer cells and protect healthy cells from premature death in disease models. The Company is currently in a Phase 1b/2a trial with a product candidate that is designed to treat B-cell cancers, which include multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin's B-cell lymphomas. Trial sites include Mayo Clinic and the Fred Hutchinson Cancer Research Center in Seattle. The technology was developed over the last 15 years through the discovery that the genetic pathway for cell growth control is common to both plants and humans.
SNTI closed the day at $3.03.
Pennypickalerts.com issues momentum alerts on stocks that can provide gains to day traders.
Pennypickalerts.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.
Pennypickalerts.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Pennypickalerts.com is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the Pennypickalerts.com newsletter and receiving alerts from a Pro-Active team of researchers. Pennypickalerts.com believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.pennypickalerts.com
Pennypickalerts.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.